Clinical Trials Logo

Clinical Trial Summary

This open-label, multicenter, dose-escalation and expansion trial is designed to evaluate the safety and preliminary efficacy of inhaled DV281 in combination with nivolumabfor the treatment of NSCLC and to select a recommended phase 2 dose (RP2D).


Clinical Trial Description

Pre-clinical studies support the proposed dosing schema to be tested and a potential benefit of the combination of inhaled DV281 with nivolumab for subjects with advanced NSCLC. This study (DV9-NSC-01) is designed for establishing an immunologically optimal RP2D for inhaled DV281 in combination with an approved anti-PD-1 inhibitor. This trial, studying the potential to enhance the efficacy of an approved anti-PD-1 inhibitor in subjects with advanced NSCLC, addresses an unmet need for NSCLC patients having tumors that do not respond or do not respond adequately to anti-PD-1 inhibitor monotherapy. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03326752
Study type Interventional
Source Dynavax Technologies Corporation
Contact
Status Completed
Phase Phase 1
Start date September 20, 2017
Completion date September 19, 2019

See also
  Status Clinical Trial Phase
Completed NCT02157883 - Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva) Phase 1
Completed NCT00072631 - Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT02163733 - Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06107374 - Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG Phase 2
Completed NCT01802632 - AZD9291 First Time In Patients Ascending Dose Study Phase 1/Phase 2
Recruiting NCT06406166 - Lifei Xiaoji Wan in Treatment of Advanced NSCLC N/A
Terminated NCT04785365 - Long-Term Follow-Up Study of Patients Receiving ATL001 Phase 2
Recruiting NCT04032847 - ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC Phase 1/Phase 2
Completed NCT01631136 - Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer Phase 3
Recruiting NCT04239443 - Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer Phase 2
Completed NCT03452150 - D-0316 First Time in Patients Ascending Dose Study Phase 1
Completed NCT04144608 - Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Not yet recruiting NCT04755738 - Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer Phase 2
Completed NCT03652857 - Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer Phase 2
Completed NCT03351361 - Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients Phase 3
Completed NCT02407327 - Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling
Active, not recruiting NCT02143466 - AZD9291 in Combination With Ascending Doses of Novel Therapeutics Phase 1
Recruiting NCT05004974 - Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer Phase 2
Recruiting NCT05777603 - Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer Phase 1
Recruiting NCT04886401 - Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients With NSCLC